This Biotech Stock Has Surged Over 100% in 2018: Is it Still a Buy Today?

Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) stock has soared in 2018, as the company has generated excitement in early trials for its lead product candidate.

| More on:
The Motley Fool

Biotechnology has received renewed interest, as investors look for alternative growth opportunities with cannabis and other markets flailing so far in 2018.

Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) is a clinical-stage biopharmaceutical company focused on the treatment of breast cancer. Shares of Zymeworks have soared 116.8% in 2018 as of close on April 30. The stock has recovered nicely from a steep drop in late May of 2017 and is now up 12.8% year over year. Zymeworks surged on news that Celgene Corporation had exercised its right to expand its collaboration agreements for the “research, development, and commercialization of biospecific antibody therapeutics using Zymeworks’ Azymetric platform.”

Zymeworks is engaged in phase one clinical trials for ZW25, its lead product candidate. ZW25 is an antibody designed to target gastric, ovarian, and breast cancer tumours. The product has yielded impressive results so far. Recently, the company announced that ZW25 had been selected for an oral presentation at the American Society of Clinical Oncology, which will be held in Chicago in early June.

Biotechnology stocks have been an explosive source of growth in recent years, but investors must also exercise a reasonable degree of caution with these speculative investments. The revenue garnered from established breast cancer drugs in the United States has generated a great deal of excitement over the prospects for Zymeworks.

Just how explosive is the growth of this industry?

The global breast cancer market has been fueled by rising healthcare expenditures, increased rates of obesity and diabetes in the population, and aging female demographics. In 2017, a report hosted by Research and Markets projected that the global breast cancer treatment market would reach $18.8 billion by 2025. This would represent a compound annual growth rate (CAGR) of 7.6% from 2017 to 2025.

Another report hosted by Global Market Insights projected that the breast cancer therapeutics market would reach $28 billion by 2024, representing a CAGR of 9%. This report cited the rising prevalence of breast cancer as well as the advancement of diagnostic and screening programs worldwide and sizable reimbursement policies. Whatever the case, the explosive potential of this market is clear. Does that mean you should invest in Zymeworks today?

Zymeworks released its 2017 fourth-quarter and full-year results on March 14. Highlights from 2017 included the results from ongoing phase 1 trials for ZW25, which we have covered already. In response to the successes, Zymeworks has expanded testing sites in the United States and Canada. Going forward, president and CEO Ali Tehrnani said that Zymeworks plans to complete enrollments in its phase one study in 2018 as well as file an Investigational New Drug application for ZW49, its second clinical compound.

In 2017, the company reported revenue of $51.8 million compared to $11 million in 2016. This was powered by the collection of a $50 million fee from its corporate partnership with Janssen. Zymeworks’s net loss in 2017 fell to $10.4 million compared to a $33.8 million loss in 2016. At the end of fiscal 2017, Zymeworks also reported it had $87.8 million in cash and cash equivalents.

The initial results for ZW25 have been promising, and further progress will undoubtedly generate excitement considering the enormous amount of revenue potential carried by breakouts in this industry.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned.

More on Tech Stocks

Businessman holding AI cloud
Tech Stocks

3 Artificial Intelligence (AI) Stocks to Buy With $500 and Hold Forever

Canadian AI stocks like Open Text Corp (TSX:OTEX) are changing the game.

Read more »

Online shopping
Tech Stocks

Should You Buy Shopify While it’s Below $100?

Here's why Shopify (TSX:SHOP) remains a top long-term growth stock investors should consider buying below the key $100 level.

Read more »

A worker uses a double monitor computer screen in an office.
Tech Stocks

Should Investors Buy Lightspeed Stock Ahead of Earnings?

Lightspeed (TSX:LSPD) stock has served a period of drama for investors in the last few months, so what can investors…

Read more »

IMAGE OF A NOTEBOOK WITH TFSA WRITTEN ON IT
Tech Stocks

TFSA Investors: 1 Top Tech Stock to Buy With $500

TFSA investors can consider owning quality tech stocks such as Datadog to benefit from outsized gains in 2024 and beyond.

Read more »

Dots over the earth connecting the world
Tech Stocks

Hot Takeaway: Concentration in 1 Stock Can Be Just Fine

Concentration in one stock can be alright under the right circumstances, and far better than buying a bunch of poor-performing…

Read more »

A worker uses a double monitor computer screen in an office.
Tech Stocks

Forget TD Stock: 2 Tech Stocks to Buy Instead

As bank stocks continue disappointing investors in 2024, you can consider adding these two top Canadian tech stocks to your…

Read more »

financial freedom sign
Tech Stocks

1 TSX Tech Stock That Has Created Millionaires and Will Continue to Make More

Constellation Software is a TSX stock tech that has delivered game-changing returns to shareholders since its IPO in 2006.

Read more »

Money growing in soil , Business success concept.
Tech Stocks

Payfare Can Potentially Provide Explosive Growth

Payfare is a global financial technology company that powers digital banking, instant payment, and loyalty reward solutions for the gig…

Read more »